NNI-362 (NNI-351)
Alzheimer's Disease
Key Facts
About Neuronascent
Neuronascent is a clinical-stage biotech pioneering a novel approach to treating neurodegenerative diseases by enhancing the brain's innate ability to generate new neurons. Its proprietary platform screens for small molecules that promote neurogenesis, neuronal migration, and survival, aiming to halt or reverse disease progression with oral therapies. The company has advanced its lead candidate, NNI-362, into clinical development for Alzheimer's disease and is exploring applications in Parkinson's disease and developmental delay. Led by founder and CEO Dr. Judith Kelleher-Andersson, Neuronascent represents a unique player in the regenerative neurology space, targeting a significant unmet medical need with a non-invasive therapeutic strategy.
View full company profileOther Alzheimer's Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| NUZ-001 | Neurizon Therapeutics | Preclinical |
| ALZN002 | Alzamend Neuro | Preclinical |
| P021 | Phanes Biotech | Preclinical |
| PB43D | Phanes Biotech | Preclinical |
| UB-311 | Vaxxinity | Phase 2 |
| Lecanemab | BioArctic | Launched |
| BAN2401 | BioArctic | Preclinical |
| Undisclosed Programs | johnson-and-johnson-innovative-medicine | Pipeline |
| MK-6240 (florquinitau) | Lantheus Medical Imaging | Regulatory Filing |
| NAV-4694 (flutafuranol) | Lantheus Medical Imaging | Phase 3 |
| LNTH-2620/PI-2620 | Lantheus Medical Imaging | Phase 3 |
| itMSCs | Stemedica Cell Technologies | Clinical Development |